Editor's note

This ExpertREACT article was originally published on 7 May 2010. Financial results and market positions described reflect the state of knowledge at that date.

Q1 2010: nearly double Q1 2009

According to VacZine Analytics' analysis, the major vaccine players sold approximately $6.5bn in Q1 2010 - nearly double the amount sold in the equivalent period of 2009. GSK was the leading company selling approximately $2.2bn (£1.41bn) followed by Novartis Vaccines at $1.36bn. Three of the five major companies (including Sanofi Pasteur) capitalised substantially on the continued production and supply of H1N1 pandemic vaccines, with H1N1 accounting for around 45% of total Q1 vaccine sales - predominantly carry-over from 2009 government orders. By the end of Q1 2010, Novartis Vaccines had shipped more than 150 million monovalent H1N1 doses since the declaration of the pandemic and had recognised approximately $2.2bn in cumulative H1N1 vaccine sales.

GSK reported an additional £698m (~$1bn) in H1N1 sales in Q1, bringing its cumulative H1N1 total since 2009 to approximately $2.4bn - though some governments had since modified their initial orders, most notably Japan, which amended its contract to receive approximately 68% of its original order in March 2010. GSK characterised the Japanese relationship as a major strategic step forward signalling the country as a priority growth area for its vaccine business.

Top 5 Q1 2010 vaccine sales
$6.5bn
Approximately double the Q1 2009 figure; H1N1 pandemic vaccines contributed ~45% of the total

MenB and Menveo as near-term catalysts

Novartis confirmed it had fulfilled the majority of 2009 H1N1 government orders and had ceased H1N1 vaccine production, with only "modest upside" guidance remaining. Novartis had recently gained US and EU approval for Menveo ACWY (for individuals over 11 years), though VacZine Analytics forecast less than $50-100m in US revenues by year-end without infant schedule recommendation. The more transformative near-term opportunity was the MenB programme - already in Phase III in Europe - with an end-of-Phase-II FDA meeting planned for Q3 2010. With the pandemic windfall beginning to fade, meningococcal vaccines were viewed as the most realistic near-term industry growth driver.